This white paper explains the benefits and challenges of microbial-based fermentation for biologics, highlighting why processes often need to be custom-built for each molecule. Outlining a streamlined, cost-effective path that accelerates development from strain selection through tox material and early GMP, to reach IND and first-in-human trials faster.
This white paper offers concise, practical guidance for biopharma teams outsourcing Process Characterization (PC) to strengthen CMC packages and accelerate commercialization.
Discover how a robust platform enables fast, high-quality bispecific antibody production by optimizing gene ratios, CLD, and analytics for purity and yield.
Discover the future of microbial expression with a platform that optimizes strain selection, expression systems, and purification methods, providing actionable insights in just eleven weeks.
Case study showcasing accelerated PPQ for an E. coli–expressed orphan therapy, achieving three PPQ batches in 18 months through high-compliance manufacturing.
A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.
Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.
Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.
Webinar Date/Time: Tue, Mar 4, 2025 11:00 AM EST
Webinar Date/Time: Wed, Dec 4, 2024 11:00 AM EST
Webinar Date/Time: Wed, Dec 6, 2023 11:00 AM EST
Published: November 15th 2023 | Updated: